JLE

Epileptic Disorders

MENU

Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring Volume 18, issue 4, December 2016

  • [Baftiu et al., 2016] Baftiu A., Johannessen Landmark C., Rusten I.R., Feet S.A., Johannessen S.I., Larsson P.G. Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications. Eur J Clin Pharmacol. 2016;72:1245-54. 10
  • [Bartoli et al., 1997] Bartoli A., Guerrini R., Belmonte A., Alessandri M.G., Gatti G., Perucca E. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit. 1997;19:252-260. 3
  • [Beardsley et al., 1983] Beardsley R.S., Freeman J.M., Appel F.A. Anticonvulsant serum levels are useful only if the physician appropriately uses them: an assessment of the impact of providing serum level data to physicians. Epilepsia. 1983;24:330-335. 3
  • [Buchthal and Svensmark, 1960] Buchthal F., Svensmark O. Aspects of the pharmacology of phenytoin (Dilantin) and phenobarbital relevant to their dosage in the treatment of epilepsy. Epilepsia. 1960;1:373-384.
  • [Burns et al., 2016] Burns M.L., Baftiu A., Opdahl M.S., Johannessen S.I., Johannessen Landmark C. Therapeutic drug monitoring of clobazam and its metabolite - impact of age and comedication on pharmacokinetic variability. Ther Drug Monit. 2016;38:350-357. 3
  • [Cascorbi, 2010] Cascorbi I. The promises of personalized medicine. Eur J Clin Pharmacol. 2010;66:749-754.
  • [Chadwick, 1987] Chadwick D.W. Overuse of monitoring of blood concentrations of antiepileptic drugs. Br Med J (Clin Res Ed). 1987;294:723-724. 6574
  • [May et al., 2012] May T.W., Boor R., Mayer T. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2012;34:390-397. 4
  • [Christensen et al., 2006] Christensen J., Sabers A., Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology. 2006;67:1497-1499. 8
  • [Commission on Antiepileptic Drugs, 1993] Commission on Antiepileptic Drugs of the International League Against Epilepsy. Guidelines for therapeutic drug monitoring of antiepileptic drugs. Epilepsia. 1993;34:585-587. 4
  • [Commission on Antiepileptic Drugs, 1989] Commission on Antiepileptic Drugs. Guidelines for clinical evaluation of antiepileptic drugs. Epilepsia. 1989;30:400-408. 4
  • [Eadie et al., 1977] Eadie M.J., Lander C.M., Tyrer J.H. Plasma drug level monitoring in pregnancy. Clin Pharmacokinetics. 1977;2:427-436. 6
  • [Ehmann et al., 2014] Ehmann F., Caneva L., Papaluca M. European Medicines Agency initiatives and perspectives on pharmacogenomics. Br J Clin Pharmacol. 2014;77:612-617. 4
  • [Eichelbaum et al., 1976] Eichelbaum M., Bertilsson L., Lund L., Palmér L., Sjöqvist F. Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy. Eur J Clin Pharmacol. 1976;9:417-421. 5–6
  • [Geffrey et al., 2015] Geffrey A.L., Pollack S.F., Bruno P.L., Thiele E.A. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56:1246-1251. 8
  • [Gulcebi et al., 2011] Gulcebi M.I., Ozkayaynacki A., Goren M.Z., Aker R.G., Özkara C., Onat F.Y. The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res. 2011;95:1-8. 1-2
  • [Haen, 2011] Haen E. Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety. Pharmacopsychiatry. 2011;44:254-258. 6
  • [Henriksen and Johannessen, 1982] Henriksen O., Johannessen S.I. Clinical and pharmacokinetic observations on sodium valproate - a 5-year follow-up in 100 children with epilepsy. Acta Neurol Scand. 1982;65:504-523. 5
  • [Hiemke and Shams, 2013] Hiemke C., Shams M. Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry. Curr Drug Deliv. 2013;10:46-53. 1
  • [Italiano and Perucca, 2013] Italiano D., Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013;52:627-645. 8
  • [Januzzi et al., 2000] Januzzi G., Cian P., Fattore C. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM study group. Epilepsia. 2000;41:222-230. 2
  • [Johannessen and Strandjord, 1972] Johannessen S.I., Strandjord R.E. The concentration of carbamazepine (Tegretol) in serum and in cerebrospinal fluid in patients with epilepsy. Acta Neurol Scand. 1972;51:445-446. ®
  • [Johannessen and Johannessen Landmark, 2010] Johannessen S.I., Johannessen Landmark C. Antiepileptic drug interactions- Basic principles and clinical implications. Current Neuropharm. 2010;8:254-267.
  • [Johannessen et al., 2003] Johannessen S.I., Battino D., Berry D.J. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25:347-363. 3
  • [Johannessen Landmark and Patsalos, 2010] Johannessen Landmark C., Patsalos P.N. Drug interactions involving the new second and third generation antiepileptic drugs. Expert Rev Neurother. 2010;10:119-140. 1
  • [Johannessen Landmark and Johannessen, 2012] Johannessen Landmark C., Johannessen S.I. Drug safety aspects of antiepileptic drugs- Focus on pharmacovigilance. Pharmacoepidemiol Drug Saf. 2012;21:11-20. 1
  • [Johannessen Landmark et al., 2011] Johannessen Landmark C., Fossmark H., Larsson P.G., Rytter E., Johannessen S.I. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res. 2011;95:51-59.
  • [Johannessen Landmark et al., 2012a] Johannessen Landmark C., Baftiu A., Tysse I. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine and topiramate-a comparison of the impact of age and comedication. Ther Drug Monit. 2012;34:440-445. 4
  • [Johannessen Landmark et al., 2012b] Johannessen Landmark C., Johannessen S.I., Tomson T. Host factors affecting antiepileptic drug delivery- Pharmacokinetic variability. Adv Drug Delivery Rev. 2012;64:896-910.
  • [Johannessen Landmark et al., 2016] Johannessen Landmark C., Svendsen T., Dinarevic J. The impact of pharmacokinetic interactions with eslicarbazepine acetate versus oxcarbazepine and carbamazepine in clinical practice. Ther Drug Monit. 2016;38:499-505. 4
  • [Karouni et al., 2010] Karouni M., Arulthas S., Larsson P.G., Rytter E., Johannessen S.I., Johannessen Landmark C. Psychiatric comorbidity in patients with epilepsy: a population-based study. Eur J Clin Pharmacol. 2010;66:1151-1160. 11
  • [Koch-Weser, 1981] Koch-Weser J. Serum drug concentrations in clinical perspective. Ther Drug Monit. 1981;3:3-16. 1
  • [Krasowski, 2010] Krasowski M.D. Therapeutic drug monitoring of the newer anti-epilepsy medications. Pharmaceuticals (Basel). 2010;3:1909-1935. 6
  • [Krasowski and McMillin, 2014] Krasowski M.D., McMillin G.A. Advances in anti-epileptic drug testing. Clin Chim Acta. 2014;436:224-236.
  • [Kutt et al., 1964] Kutt H., Wintes W., Kokenge R., McDowell F. Diphenylhydantoin metabolism, blood levels, and toxicity. Arch Neurol. 1964;11:642-648.
  • [Lee et al., 2007] Lee S.Y., Lee S.T., Kim J.W. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. J Biochem Mol Biol. 2007;40:448-452. 3
  • [Lesko and Schmidt, 2012] Lesko L.J., Schmidt S. Individualization of drug therapy: history, present state, and opportunities for the future. Clin Pharmacol Ther. 2012;92:458-466. 4
  • [Löscher et al., 2009] Löscher W., Klotz U., Zimprich F., Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 2009;50:1-23. 1
  • [Lund, 1974] Lund L. Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures. Arch Neurol. 1974;31:289-294. 5
  • [Løyning, 1983] Løyning L. Antiepileptic drugs. In: Sakshaug S., Andrew M., Hjort P.F., Lunde P.K.M., Øydvin K., eds. Drug utilization in Norway during the 1970s-increases, inequalities and innovations. Oslo, Norway: The Norwegian Medicinal Depot; 1983. 197-201
  • [Markoula et al., 2014] Markoula S., Teotonio R., Ratnaraj N., Duncan J.S., Sander J.W., Patsalos P.N. Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs. Ther Drug Monit. 2014;36:494-498. 4
  • [Meijer et al., 1973] Meijer J.W.A., Meinardi H., Gardener-Thorpe C., Kleijn E., van der. Methods of analysis of anti-epileptic drugs. Amsterdam: Excerpta Medica (New York: American Elsevier); 1973.
  • [Nunes et al., 2013] Nunes T., Rocha J.F., Falcao A. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia. 2013;54:108-116. 1
  • [Öhman et al., 2000] Öhman I., Vitols S., Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia. 2000;41:709-713. 6
  • [Patsalos et al., 2008] Patsalos P.N., Berry D.J., Bourgeois B.F. Antiepileptic drugs- best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239-1276. 7
  • [Patsalos and Berry, 2013] Patsalos P.N., Berry D.J. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Ther Drug Monit. 2013;35:4-29.
  • [Patsalos et al., 2016] Patsalos P.N., Gougoulaki M., Sander J.W. Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex, and concomitant anti-epileptic drugs. Ther Drug Monit. 2016;38:358-364. 3
  • [Pennell et al., 2004] Pennell P.B., Newport D.J., Stowe Z.N., Helmers S.L., Montgomery J.Q., Henry T.R. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology. 2004;62:292-295. 2
  • [Perucca, 2000] Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet. 2000;38:191-204. 3
  • [Perucca et al., 2008] Perucca E., Cloyd J., Critchley D., Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123-1141. 7
  • [Pippenger et al., 1978] Pippenger C.E., Penry J.K., Kutt H. Antiepileptic drugs: quantitative analysis and interpretation. New York: Raven Press; 1978.
  • [Reimers et al., 2005] Reimers A., Helde G., Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia. 2005;46:1414-1417. 9
  • [Reimers et al., 2016] Reimers A., Sjursen W., Helde G., Brodtkorb E. Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine. Eur J Drug Metab Pharmacokinet. 2016;41:149-155. 2
  • [Richens, 1975a] Richens A. Serum phenytoin levels in management of epilepsy. Lancet. 1975;2:247-248.
  • [Richens, 1975b] Richens A. Quality control of drug estimations. Acta Neurol Scand Suppl. 1975;S60:81-84.
  • [Sabers et al., 2003] Sabers A., Öhman I., Christensen J., Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology. 2003;61:570-571. 4
  • [Samsonsen et al., 2014] Samsonsen C., Reimers A., Bråthen G., Helde G., Brodtkorb E. Nonadherence to treatment causing acute hospitalizations in people with epilepsy: an observational, prospective study. Epilepsia. 2014;55:e125-e128. 11
  • [Schmidt and Haenel, 1984] Schmidt D., Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: individual variation in relation to seizure frequency and type. Neurology. 1984;34:1252-1255. 9
  • [Schmidt et al., 1986] Schmidt D., Einicke I., Haenel F. The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital, and carbamazepine. Arch Neurol. 1986;43:263-265. 3
  • [Shah et al., 2013] Shah N.M., Hawwa A.F., Millership J.S., Collier P.S., McElnay J.C. A simple bioanalytical method for the quantification of antiepileptic drugs in dried blood spots. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;923-4:65-73.
  • [Shorvon et al., 1978] Shorvon S.D., Chadwick D., Galbraith A.W., Reynolds E.H. One drug for epilepsy. Br Med J. 1978;1:474-476. 6111
  • [Shorvon et al., 1980] Shorvon S.D., Galbraith A.W., Laundy M., Vydelingum L., Reynolds E.H. Monotherapy for epilepsy. In: Johannessen S.I., Morselli P.L., Pippenger C.E., Richens A., Schmidt D., Meinardi H., eds. Antiepileptic therapy: advances in drug monitoring. New York: Raven press; 1980. 213-9
  • [Sirot et al., 2006] Sirot J.E., van der Velden J.W., Rentsch K., Eap C.B., Baumann P. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf. 2006;29:735-768. 9
  • [St Louis, 2009] St Louis E.K. Monitoring antiepileptic drugs: a level-headed approach. Curr Neuropharmacol. 2009;7:115-119. 2
  • [Strandjord and Johannessen, 1972] Strandjord R.E., Johannessen S.I. One daily dose of diphenylhydantoin (DPH) to patients with epilepsy. Acta Neurol Scand Suppl. 1972;51:499-500.
  • [Strandjord and Johannessen, 1980] Strandjord R.E., Johannessen S.I. Single-drug therapy with carbamazepine in patients with epilepsy: serum levels and clinical effect. Epilepsia. 1980;21:655-662. 6
  • [Tomson, 1984] Tomson T. Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Arch Neurol. 1984;41:830-834. 8
  • [Tomson and Johannessen, 2000] Tomson T., Johannessen S.I. Therapeutic drug monitoring of new antiepileptic drugs. Eur J Clin Pharmacol. 2000;55:697-705. 10
  • [Tomson et al., 2007a] Tomson T., Palm R., Källén K. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia. 2007;48:1111-1116. 6
  • [Tomson et al., 2007b] Tomson T., Dahl M.L., Kimland E. Therapeutic drug monitoring of antiepileptic drugs for epilepsy. Cochrane Database Syst Rev. 2007;1:CD002216.
  • [Tomson et al., 2013] Tomson T., Johannessen Landmark C., Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013;54:405-414. 3
  • [Westin et al., 2009] Westin A.A., Nakken K.O., Johannessen S.I., Reimers A., Lillestølen K.M., Brodtkorb E. Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia. 2009;50:480-485. 3
  • [Williams et al., 2003] Williams J., Bialer M., Johannessen S. Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. Epilepsia. 2003;44:40-45. 1
  • [Wilson et al., 1989] Wilson J.F., Tsanaclis L.M., Williams J., Tedstone J.E., Richens A. Evaluation of assay techniques for the measurement of antiepileptic drugs in serum: a study based on external quality assurance measurements. Ther Drug Monit. 1989;11:185-195. 2
  • [Woodbury et al., 1972] Antiepileptic Drugs. In: Woodbury D.M., Penry J.K., Schmidt R.P., eds. USA: Raven Press; 1972.
  • [Yasiry and Shorvon, 2012] Yasiry Z., Shorvon S. How phenobarbital revolutionized epilepsy therapy: the story of phenobarbital therapy in epilepsy in the last 100 years. Epilepsia. 2012;53:26-39. 8